Marksans Pharma (MARKSANS) Hisse Özeti
Marksans Pharma Limited, bağlı ortaklıklarıyla birlikte Amerika Birleşik Devletleri, Kuzey Amerika, Avrupa, Birleşik Krallık, Avustralya, Yeni Zelanda ve uluslararası alanda farmasötik formülasyonların araştırılması, üretimi, pazarlanması ve satışı ile ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 2/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 3/6 |
MARKSANS Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Marksans Pharma Limited Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | ₹216.17 |
| 52 Haftanın En Yüksek Seviyesi | ₹270.70 |
| 52 Haftanın En Düşük Seviyesi | ₹155.00 |
| Beta | 0.98 |
| 1 Aylık Değişim | 22.29% |
| 3 Aylık Değişim | 21.19% |
| 1 Yıllık Değişim | -12.41% |
| 3 Yıllık Değişim | 195.31% |
| 5 Yıllık Değişim | 188.42% |
| Halka arzdan bu yana değişim | 694.89% |
Son Haberler & Güncellemeler
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...Recent updates
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...
MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum
Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Developed Markets Will Support Affordable Generic Expansion
Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Hissedar Getirileri
| MARKSANS | IN Pharmaceuticals | IN Pazar | |
|---|---|---|---|
| 7D | 7.1% | 1.5% | -0.2% |
| 1Y | -12.4% | 11.3% | 0.02% |
Getiri vs. Endüstri: MARKSANS geçen yıl % 11.3 oranında getiri sağlayan Indian Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: MARKSANS geçen yıl % 0 oranında getiri sağlayan Indian Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| MARKSANS volatility | |
|---|---|
| MARKSANS Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.8% |
İstikrarlı Hisse Senedi Fiyatı: MARKSANS son 3 ayda Indian piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: MARKSANS 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1992 | 1,840 | Mark Saldanha | marksanspharma.com |
Marksans Pharma Limited, bağlı ortaklıkları ile birlikte Amerika Birleşik Devletleri, Kuzey Amerika, Avrupa, Birleşik Krallık, Avustralya, Yeni Zelanda ve uluslararası alanda farmasötik formülasyonların araştırılması, üretimi, pazarlanması ve satışı ile ilgilenmektedir. Şirket ağrı yönetimi, üst solunum, kardiyovasküler, merkezi sinir sistemi, anti-diyabetik, gastrointestinal, analjezikler, üst solunum, kulak bakımı, cilt bakımı, antikanser, anti-ülseratif, anti-alerji, antiviral, diyet, kardiyak, dermatoloji, antihistaminikler, anti-fungal, anti-viral, laksatifler ve soğuk algınlığı ve öksürük terapötik alanlarında ürünler sunmaktadır. Şirket ayrıca tabletler ve sert jelatin kapsüller; yumuşak jeller; uçucu yağlar; merhemler; kremler ve sıvıların yanı sıra reçeteli ilaçlar da dahil olmak üzere bir dizi katı oral dozaj formu üretmektedir.
Marksans Pharma Limited Temel Bilgiler Özeti
| MARKSANS temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | ₹97.96b |
| Kazançlar(TTM) | ₹3.60b |
| Gelir(TTM) | ₹28.03b |
MARKSANS aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| MARKSANS gelir tablosu (TTM) | |
|---|---|
| Gelir | ₹28.03b |
| Gelir Maliyeti | ₹12.66b |
| Brüt Kâr | ₹15.37b |
| Diğer Giderler | ₹11.77b |
| Kazançlar | ₹3.60b |
Son Raporlanan Kazançlar
Dec 31, 2025
Sonraki Kazanç Tarihi
May 26, 2026
| Hisse başına kazanç (EPS) | 7.95 |
| Brüt Marj | 54.83% |
| Net Kâr Marjı | 12.85% |
| Borç/Özkaynak Oranı | 12.2% |
MARKSANS uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/21 08:03 |
| Gün Sonu Hisse Fiyatı | 2026/05/21 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Marksans Pharma Limited 5 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Deepika Murarka | Choice Equity Broking Private Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |